Prospective Phase II Study of Preoperative Chemoradiation with Capecitabine in Locally Advanced Rectal Cancer

Park, Jin‐Hong; Kim, Jong Hoon; Ahn, Seung Do; Lee, Sangwook; Shin, Seong Sik; Kim, Jin Cheon; Yu, Chang Sik; Kim, Hee Cheol; Kang, Yoon‐Koo; Kim, Tae Won; Chang, Heung Moon; Ryu, Min Hee; Choi, Eun Kyung

doi:10.4143/crt.2004.36.6.354

Cited by 10 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, it may enable sphincterpreserving resection in patients with low rectal tumors through downstaging of locally advanced disease [70]. The post-CRT restaging MRI examination is performed with the intent to, again, ensure negative margins, select patients with preexisting morbidities for local or less radical excision, and reassess patients for interval development of metastasis and extramesorectal lymphadenopathy.…”

Section: Assessment Of Responsementioning

confidence: 99%

MRI of Rectal Cancer: An Overview and Update on Recent Advances

Jhaveri

Hosseini-Nik

2015

American Journal of Roentgenology

141

View full text Add to dashboard Cite

show abstract

Section: Assessment Of Responsementioning

confidence: 99%

MRI of Rectal Cancer: An Overview and Update on Recent Advances

Jhaveri

Hosseini-Nik

2015

American Journal of Roentgenology

141

View full text Add to dashboard Cite

show abstract

“…In a preclinical study, capecitabine given orally resulted in consistently higher tissue-to-plasma 5-FU concentration ratios than 5-FU administered intravenously . In addition, capecitabine has also exhibited antitumour activity when given as a monotherapy or in combination with cisplatin in patients with various solid tumours as well as in advanced HNSCC (Blum et al, 1999;Van Cutsem et al, 2001;Kim et al, 2002;Pivot et al, 2003;Park et al, 2004).…”

mentioning

confidence: 99%

Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck

et al. 2005

View full text Add to dashboard Cite

We aimed to evaluate the efficacy and safety of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). In total, 37 patients with stage III or IV SCCHN were enrolled on the study. The chemotherapy consisted of two cycles of intravenous cisplatin of 80 mg m À2 on day 1 and oral capecitabine 825 mg m À2 twice daily from day 1 to day 14 at 3-week intervals. The radiotherapy (1.8 -2.0 Gy 1 fraction day À1 to a total dose of 70 -70.2 Gy) was delivered to the primary tumour site and neck. The primary tumour sites were as follows: oral cavity (n ¼ 6), oropharynx (n ¼ 11), hypopharynx (n ¼ 8), larynx (n ¼ 3), nasopharynx (n ¼ 6), and paranasal sinus (n ¼ 3). After the chemoradiotherapy, 29 complete responses (78.4%) and 6 partial responses (16.2%) were confirmed. Grade 3 or 4 neutropenia occurred only in two patients, plus grade 3 febrile neutropenia was observed only in one patient. At a median follow-up duration of 19.8 months, the estimated overall survival and progression-free survival rate at 2-year was 76.8 and 57.9%, respectively. Concurrent chemoradiotherapy with capecitabine and cisplatin was found to be well tolerated and effective in patients with locally advanced SCCHN.

show abstract

“…A number of prospective studies have also shown the efficacy and favorable safety profile of capecitabine as a radiosensitizer over other commonly used chemotherapeutic agents like cisplatin and 5-FU when treating many solid tumors, including head and neck cancer (11)(12)(13)(14)17,(19)(20)(21)24). The overall survival and progression-free survival rate in these studies at 2 years were 76.8% and 57.9%, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…There is evidence that radiation leads to the upregulation of thymidine phosphorylase expression, thereby synergizing the action of capecitabine (9). Mounting evidence suggests that oral capecitabine, which mimics continuous 5-FU infusion, has substantial activity in squamous cell carcinoma of the head and neck (10,11) and is replacing 5-FU in the treatment of many solid tumors as well as in advanced head and neck squamous cell carcinoma (12)(13)(14)(15)(16)(17)(18)(19)(20). Thus, the impact of radiation-induced toxicity on quality of life and treatment compliance justifies the use of concurrent chemoradiotherapy with an oral capecitabinebased regimen.…”

Section: Introductionmentioning

confidence: 99%

Clinical benefits of concurrent capecitabine and cisplatin versus concurrent cisplatin and 5-flurouracil in locally advanced squamous cell head and neck cancer

Gupta

Khan²,

Barik³

et al. 2013

Drug Discov Ther

View full text Add to dashboard Cite

We aimed to assess the efficacy and safety of concurrent capecitabine and cisplatin over concurrent cisplatin and 5-flurouracil (5-FU) in locally advanced squamous cell carcinoma of the head and neck. One hundred and fifty-three patients (all of whom had stage III or IV unresectable disease with no distant metastases and who had received two cycles of taxol and cisplatin chemotherapy) were randomly assigned to receive either concurrent cisplatin (75 mg/m 2 in day 1 and 2) and 5-FU (750 mg/m 2 in day 1, 2, and 3) from the first day of radiotherapy at an interval of 3 weeks (Arm I) or cisplatin (75 mg/m 2 in day 1 and 2) and capecitabine (750 mg/m 2 in two divided doses from day 1-14) from the first day of radiotherapy at a 3-week interval (Arm II). Results showed that patients in Arm II had a significantly better rate of complete response, fewer nodes, and better overall response compared to those in Arm I. The two groups had a similar 3-year disease-free survival, progressionfree survival, and overall survival, i.e. they did not differ significantly. Variables indicating the quality of life of the two groups were compared. Patients in Arm II had a significantly higher quality of life compared to those in Arm I. The two groups had similar treatment-related acute and late toxicity, i.e. they did not differ significantly. These results have thoroughly substantiated the contention that concurrent chemoradiation with capecitabine and cisplatin may be regarded as an effective and welltolerated regimen in the treatment of the patients with locally advanced head and neck cancer.

show abstract

Prospective Phase II Study of Preoperative Chemoradiation with Capecitabine in Locally Advanced Rectal Cancer

Cited by 10 publications

References 24 publications

MRI of Rectal Cancer: An Overview and Update on Recent Advances

MRI of Rectal Cancer: An Overview and Update on Recent Advances

Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck

Clinical benefits of concurrent capecitabine and cisplatin versus concurrent cisplatin and 5-flurouracil in locally advanced squamous cell head and neck cancer

Contact Info

Product

Resources

About